MaxCyte, Inc. (LON:MXCT – Get Free Report) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 346 ($4.35) and traded as low as GBX 264 ($3.32). MaxCyte shares last traded at GBX 264 ($3.32), with a volume of 29,582 shares.
MaxCyte Trading Down 2.6 %
The stock has a market cap of £348.49 million, a PE ratio of -9.67 and a beta of 1.13. The company has a current ratio of 9.81, a quick ratio of 14.38 and a debt-to-equity ratio of 8.59. The firm has a fifty day simple moving average of GBX 344.76 and a two-hundred day simple moving average of GBX 313.89.
MaxCyte Company Profile
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Read More
- Five stocks we like better than MaxCyte
- Where Do I Find 52-Week Highs and Lows?
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- Dividend Capture Strategy: What You Need to Know
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- Stock Splits, Do They Really Impact Investors?
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.